STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8
Clinical trials for STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for bile duct cancer: targeted drug shows promise in early trial
Disease control OngoingThis study tests a drug called sacituzumab govitecan in people with bile duct cancer that has spread or come back after treatment. The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a toxic payload to kill them. The trial includes 15 adults an…
Matched conditions: STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New combo therapy targets tough bile duct cancer
Disease control OngoingThis early-phase trial tests a new approach for people with advanced bile duct cancer that has spread. It combines a special type of radiation (given in fewer, stronger doses) with an immunotherapy drug called bintrafusp alfa, which helps the immune system fight cancer. The goal …
Matched conditions: STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New drug cocktail shows promise for Tough-to-Treat biliary cancers
Disease control OngoingThis study tests whether adding the targeted drug binimetinib to standard chemotherapy (mFOLFOX6) can shrink tumors or improve survival in people with advanced biliary tract cancers (bile duct or gallbladder) that have specific genetic changes (MAPK pathway mutations). About 66 a…
Matched conditions: STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 07, 2026 18:42 UTC